Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0232
Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0396
Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
Systemic Sclerosis & Related Disorders – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 0236
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0203
Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0223
Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB)
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0202
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0237
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0346
Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0411
Serial Vessel Wall Enhancement Change on High-Resolution MRI Vessel Wall Imaging in Primary Central Nervous System Vasculitis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I- 9:00AM-11:00AM
-
Abstract Number: 0253
Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0384
Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease
Systemic Sclerosis & Related Disorders – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 0383
Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials
Systemic Sclerosis & Related Disorders – Clinical Poster I